Imunon Inc (IMNN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.40 (+1.45%), Market cap $0.01B, 52-week low–high $2.49 ~ $32.74.
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCi
Financial statements, price targets, institutional (13F) holdings and related news for Imunon Inc are updated in real time on BlackAll Trade.
Imunon Inc trades at $1.40 (+1.45%). Real-time quotes and charts are available on BlackAll Trade.
Imunon Inc has a market cap of about $0.01B.
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherap